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Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) arose as a novel virus
in Wuhan China in December 2019. Then, as it rapidly spread across the world, it was declared a
global health emergency by the World Health Organization in March 2020. SARS-CoV-2, the
causative agent of coronavirus disease 2019 (COVID-19), has dramatically disrupted both
normal life and the economy. In the past year and a half, there have been over 175 million cases
globally1 (as of June 15, 2021). High death rates, disruption to education, and widespread job
loss has necessitated the desperate need for a vaccine against SARS-CoV-2. A vaccine against
SARS-CoV-2 will significantly reduce the spread of COVID-19 and enable a safe return to
pre-pandemic social life. Across the world, money and research have been poured into the
vaccine, resulting in the fastest vaccine development in history. The Pfizer-BioNtech mRNA
vaccine, one of the first widely available vaccines, was approved by emergency authorization in
Britain on December 2, 2020, and then by the Food and Drug Administration (FDA) in the
United States on December 11, 2020. Soon after, on December 18, the Moderna vaccine, another
mRNA vaccine, was also approved for emergency use2. There are several different vaccines in
production and under development, but the focus of this paper is specifically on the Pfizer and
Moderna mRNA vaccines, and the antibody responses these vaccines elicit based on the use of
the spike protein as an antigen. The binding of antibodies, generated through vaccination, to the
spike protein of SARS-CoV-2 effectively neutralizes the virus, and understanding the details of
the interactions between the spike protein and different antibodies is essential for understanding
the specifics of the immune response to SARS-CoV-2 upon which the vaccine is based and the
effect novel variants may have on the effectivity of the vaccine.
Basic Biology of SARS-CoV-2
The SARS-CoV-2 genome was first published on January 10, 2020. SARS-CoV-2 is a
Betacoronavirus, belonging to the same genus as SARS-CoV-1 and Middle-East Respiratory
Syndrome Coronavirus (MERS-CoV) as well as two common cold coronaviruses, HCoV-OC43
and HCoV-HKU13,4,5. The SARS-CoV-2 virus is an enveloped positive sense RNA virus. It
consists of a helical ribonucleocapsid complex made of nucleocapsid proteins and the messenger
RNA (mRNA) sequence which holds all of the essential genes for the virus surrounded by a
membrane which protects the mRNA and allows the virus to fuse with the membrane of host
cells. The membrane of the virus is populated with proteins, including the famed spike protein
which allow the virus to bind to host cells. SARS-CoV-2 has four structural proteins and 16
nonstructural proteins. The four structural proteins include the membrane protein which
organizes the formation of the viral membrane, the envelope protein, which like the membrane
protein is incorporated in the viral membrane and helps facilitate new viral assembly, the
nucleocapsid protein, and the spike protein3 (Fig. 1). By October 2020, the structures of more
than half of the SARS-CoV-2 proteins had been determined using Cryo-Electron-Microscopy
(Cryo-EM) and X-ray crystallography.
Figure 1: Schematic representation of a SARS-CoV-2 virus (created  using BioRender). The four structural proteins
are labeled.
Viral Life Cycle
SARS-CoV-2 invades host cells and utilizes host cell components to replicate, producing
new virions which can spread to and infect other cells (Fig. 2). The SARS-CoV-2 spike protein,
which is expressed on the outside of the viral membrane, binds to receptors on the host cell
membrane. After the spike protein binds to the host cell, the virus either fuses with the host cell
membrane and the viral mRNA is released into the host cell, or the virus is engulfed into the cell
through endocytosis5. Once inside the host cell, the viral mRNA is released from the membrane
and uncoated from the nucleocapsid proteins5. Ribosomes in the cell then translate the viral
mRNA into proteins.
Figure 2: Complete viral life cycle of SARS-CoV-2. Entry by membrane fusion is not shown. source: Chilamakuri,
R. & Argarwal, S. (2021). COVID-19: Characteristics and therapeutics. Cells. 10(2).
https://doi.org/10.3390/cells10020206
The first open reading frame (Orf) of the viral genome to be translated is Orf1ab.
Translation of Orf1ab produces polyprotein a and polyprotein ab which encode the 16
non-structural proteins (nsps)5,6. These polyproteins are cleaved by proteases from nsp3 and
nsp5, contained in the downstream region of the genome. Cleavage of the polyproteins results in
the nonstructural proteins which make up the replication and transcription complex (RTC),
including the RNA-dependent RNA polymerase (RdRP)6. The viral RNA is then replicated to
generate new mRNA which is packaged in new viruses or translated into new viral proteins.
Discontinuous negative strand synthesis from the 3’ end of the viral genomic mRNA produces
nested mRNAs which are translated into structural and accessory proteins5.  Membrane and
envelope proteins interact with the host cell endoplasmic reticulum (ER) to initiate the formation
of new viral envelopes and the engulfment of newly replicated mRNA, prompting the generation
of new virions. The new virions then exit the cell through exocytosis5.
Structure of the Spike Protein
The spike protein is a homotrimeric glycoprotein expressed on the outside of the
SARS-CoV-2 viral membrane. Many studies have been done to elucidate a detailed image of the
molecular structure of the spike protein through the use of Cryo-EM and X-ray crystallography.
The spike protein has two distinct subunits, the S1 subunit and the S2 subunit7,8. The S1 subunit
is the receptor binding fragment while the S2 subunit is the fusion fragment. The S1 subunit is
located on the top of the spike protein and protects the prefusion S27. The S1 subunit contains an
N-terminal domain (NTD), the receptor binding domain (RBD), and two C-terminal domains
(CTD)7. The S2 subunit is made of a central helix (CH), comprised of a three-stranded coiled
coil, connected by the connector domain to the C-terminal heptad repeat 2 (HR2), heptad repeat
1 (HR1), the fusion peptide (FP), which becomes inserted in the host cell membrane, and a
transmembrane segment (TM) which anchors the spike protein in the viral membrane7.
Figure 3: (A) Cartoon representation of the spike protein structure. Each domain is labeled and highlighted in a
different color. (B) Schematic representation of the expression construct of the full-length SARS-CoV-2 spike
protein. Glycans are represented by the tree-like symbols in black. Source: Cai, Y., Zhang, J., Xiao, T., Peng, H., &
Sterling, S. (2020). Distinct conformational states of SARS-CoV-2 spike protein. Science, 369(6511).
https://doi.org/10.1126/science.abd4251
The spike protein has 22 glycans, or polysaccharide chains, on each trimer3. It has been
suggested that N-linked glycans on the surface of the spike protein may have a function in
inducing non-neutralizing antibodies in order to evade the immune system by shielding critical
epitopes from other neutralizing anitbodies3,7, a function that has been seen in HIV and influenza
viral proteins7. Additionally, the presence of glycans may contribute to the conformational
stability of the RBD3.
The receptor binding domain of SARS-CoV-2 binds to the peptidase domain of
angiotensin-converting enzyme (ACE2), a receptor protein expressed on the surface of host cells.
The high affinity between ACE2 and the SARS-CoV-2 spike protein has been suggested to
contribute to the high transfectability of the virus7. As described by Papageorgiou and Mohsin in
a review of the SARS-CoV-2 spike protein, “The RBD is characterized by a twisted
five-stranded antiparallel β-sheet with a long insertion between β4 and β7”. This insertion
interacts with two loops in the N-terminal peptidase domain of ACE2 in RBD binding to ACE2 3
(FIG. 4A). The RBD can be in either an up or down position (Fig. 4 B&C). The down position is
receptor-inaccessible and is more stable, while the up position is receptor-accessible and less
stable7. When the RBD binds to ACE2 and all RBDs are in the up position, the spike protein
undergoes a conformational change which allows membrane fusion to occur7.
Figure 4: (A) The insertion between β4 and β7 of the RBD, shown in green, interacts with ACE2. PDB ID: 6LZG.
RBDs, highlighted in green, on the spike protein in the (B) three down and (C) two down, one up conformations.
The RBD in the up position is shown in yellow. PDB ID: 6XM5 and 6XKL.
Conformation Change of the Spike Protein
The spike protein has two different conformational shapes, a pre-fusion conformation and
a post-fusion conformation. The pre-fusion conformational state is metastable, while the
post-fusion conformation state is stable7. RBD binding to ACE2 leads to a 3-RBD-up
conformation7. When all three RBDs are in the up position, the spike protein is highly unstable.
This increased instability causes the S1 subunit to dissociate from the S2 subunit, subsequently
causing the S2 subunit to change conformation3,7,8. Cleavage of the S1/S2 cleavage site also
contributes to the complete dissociation of the S1 subunit7. When the S1 subunit dissociates, the
S2’ cleavage site adjacent to the fusion peptide is exposed1 and cleaved by host cell proteases,
transmembrane serine protease TMPRSS2 or cysteine proteases cathepsin B and cathepsin L5,6,7.
This cleavage releases the fusion peptide3. Additionally, in the transition between pre and
post-fusion states the HR1 domain of the S2 subunit flips and HR2 folds back, inserting the
fusion peptide in the host cell membrane and allowing the fusion peptide and the transmembrane
segment to become in close proximity and facilitate membrane bending during fusion7. The
conformational change of the spike protein from a metastable pre-fusion to a stable post-fusion
conformation allows viral fusion to overcome the kinetic energy barrier of membrane fusion, and
proceed in a thermodynamically favorable manner7.
Spike Protein Based mRNA Vaccines
The Food and Drug Administration has authorized the emergency use of three vaccines
against COVID-19 in the United States. Two of those vaccines are the Pfizer-BioNTech
(BNT163b2) and Moderna (mRNA 1273) mRNA vaccines. These mRNA vaccines are
comprised of a mRNA molecule which codes for a modified spike protein encased in a lipid
nanoparticle. The lipid nanoparticle protects the mRNA sequence from degradation by host
enzymes13 and facilitates its delivery to host cells. The mRNA within the Pfizer and Moderna
vaccines encodes a full-length SARS-CoV-2 spike protein with two stabilizing proline mutations
in the C-terminal domain of the S2 subunit8,9.
Once the vaccine is administered, the lipid nanoparticle is taken up by a host cell, and
using host cell ribosomes, the mRNA it contains is translated into spike proteins2. The spike
proteins and spike protein fragments made by the cell are then presented on the cell surface
where they are able to be recognized by the immune system2. Essentially, mRNA vaccines use a
mRNA transcript to produce a spike protein in order to elicit a neutralizing antibody response
and file SARS-CoV-2 in the immune system’s memory. Due to its role in receptor binding and
fusion, the spike was identified as an antigenic target early in the pandemic8.
The immune system works to recognize and respond to foreign materials, such as the
spike proteins now expressed by cells in a vaccinated individual, through a complex pathway
involving many different cell types (Fig. 5). If a cell expressing spike proteins dies, an
antigen-presenting cell may take up spike proteins and fragments from the cell debris. The
antigen-presenting cell then digests the spike protein and presents the spike protein fragments on
its surface to be recognized by helper T cells. Helper T cells are activated by the antigens
presented on the surface of the antigen-presenting cells, and activated helper T cells may
function to activate either killer T cells or B cells. Activated killer T cells target and kill cells that
have been infected. B cells interact with spike proteins on the surface of an infected, or
vaccinated, cell, and if activated by helper T cells will either secrete soluble antibodies against
the spike protein or will proliferate into memory cells. Memory B cells become a part of the
innate immune system until activated by a specific antigen, such as the spike protein, which
causes them to become active and secrete antibodies. Antibodies produced by the B cells will
respond to the presence of the virus, neutralizing it by marking virions for destruction, and in
some cases, preventing them from binding to the ACE2 receptor. A rapid immune response to the
virus prevents infection and decreases viral load, reducing transfectability.
Figure 5: The immune system response elicited by the mRNA vaccine (created using BioRender).
In a study on mRNA vaccine-elicited antibodies, Zijun Wang et al. found that the mRNA
vaccines provoke a very similar B cell memory immune response as natural infection by
SARS-CoV-210. Furthermore, the antibodies produced by individuals given either the Pfizer or
Moderna vaccine were almost identical10. These findings allow antibodies produced by natural
infection in COVID-19 patients to be considered in analysis of antibody-spike protein
interactions elicited by either mRNA vaccine.
Spike-Protein Antibody Interactions
Using serum from convalescent COVID-19 patients, researchers have identified many
monoclonal neutralizing antibodies against the SARS-CoV-2 spike protein. Additionally,
multiple overlapping epitopes have been identified on the spike protein, the majority of which
are located on either the RBD or the NTD13. Antibodies that target the RBD have been found to
be more potently neutralizing against SARS-CoV-2 than antibodies targeting the NTD or other
regions of the spike protein, as blocking the SARS-CoV-2 RBD from binding with ACE2
prevents viral entry to the host cell10,13. Wu et al. expressed the SARS-CoV-2 RBD to isolate B
cells from COVID-19 patients. From this experiment they found four neutralizing antibodies,
B5, B38, H2, and H4 which bound specifically to the RBD of SARS-CoV-2 and not to the RBD
of SARS-CoV-1. Antibody specificity for SARS-CoV-2 suggests that the two SARS viruses
have different epitopes within their RBDs11. The spike proteins of SARS-CoV-2 and
SARS-CoV-1 share 77.5 percent amino acid sequence identity, while the spike proteins of
SARS-CoV-2 and MERS share only 31 percent sequence identity4. These differences in sequence
account for the binding of unique antibodies. The B38 antibody was also identified in a proteome
microarray experiment conducted by Hongye Wang et al, and further assays showed that the B38
and H4 antibodies compete with ACE2 for binding with the RBD11,12.
The B38 antibody interacts with 36 residues in the RBD, 15 with the light chain of the
antibody and 21 with the heavy chain3,11. Eighteen of the RBD residues that interact with B38
also are a part of the 21 residues on the RBD which have been found to interact with ACE211
(Fig 6), strong evidence showing binding competition between ACE 2 and B38. The interaction
between the spike protein RBD and the B38 antibody is based mainly on hydrophilic
interactions3. Using the PyMOL measurement tool, 14 potential hydrogen bonds were found
between the side chains of B38 and the previously identified 36 interacting residues of the RBD.
Potential hydrogen bonds were identified by measurements of 2.5-4.0Å between oxygen and
nitrogen atoms of the side chains (Fig. 7).
Figure 6: (A) The 21 residues on the RBD that interact with ACE2 are colored in. PDB ID: 6LZG. Cyan residues are
specific to interaction with ACE2. Green colored residues interact with both ACE2 and (B) B38. PDB ID; 7BZ5.
Figure 7: Representative images of the hydrogen bonds between the RBD and B38. Side chains are colored by atom
and potential hydrogen bonds are shown with dashed lines.
Mice infected with COVID-19 and given either B38 or H4 had significantly lower
amounts of viral RNA three days post-infection than mice in the control group that were not
given B38 or H4 antibodies11 (Fig. 8), demonstrating the neutralizing capacity of these two
antibodies.
Figure 8: Viral RNA copies measured by q-RT-PCR in mice lungs  treated with B38, H4, or phosphate buffered
saline (PBS) 3 days post-infection with COVID-19. source: Wu, Y., Wang, F., Shen, C. et al. (2020). A
noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.
B38 and H4 bind to different, but overlapping epitopes on the RBD11, as can be seen in
the PyMOL alignment in Figure 9A. In a competition assay for B38 and H4, Wu et al. found that
after saturation with the first antibody, the second antibody still bound to the RBD, which shows
that B38 and H4 are noncompetitive11. A BLAST alignment of the B38 and H4 Fabs shows
several differences between the two antibodies in both the heavy and light chains (Fig. 9B),
consistent with previous evidence for distinct epitope recognition.
Figure 9: (A) PyMOL alignment of B38 and H4. RBDs are aligned. PDB ID: 7BZ5 and 6ZH9. (B) BLAST
alignment of B38 and H4 heavy chains. (C) BLAST alignment of B38 and H4 light chains. Variable residues are
highlighted in the BLAST alignments..
A PyMOL alignment and BLAST alignment was also done between B38 and C105 (Fig.
10), an antibody isolated from the plasma of a COVID-19 patient via ELISA4. C105 shares an
epitope with B38 and forms a complex with the spike with either 2 or 3 RBD in the up position,
in which an antibody binds to each RBD in the up position. The heavy chains of B38 and C105
are derived from the same gene, VH3-53, but the light chains are derived from different genes,
KV1-9 and LV2-8 respectively4. This difference can be seen in the BLAST alignment of B38 and
C105. Researchers have observed an overexpression of IGHV3-53 and IGHV3-30 derived
antibodies among anti-SARS-CoV-2 mAbs4,13 produced by both natural infection and
vaccination10. This finding suggests that the memory B cell response to the spike protein is
relatively similar between natural infection and vaccination and across the Pfizer and Moderna
vaccines.
Figure 10: (A) PyMOL alignment of B38 and C105. PDB ID: 7BZ5 and 6XCA. (B) BLAST alignment of B38 and
C105  heavy chains. (C) BLAST alignment of B38 and C105 light chains. Variable residues are highlighted.
The Future of mRNA Vaccines
The development of the Pfizer and Moderna mRNA vaccines, in addition to being a key
to moving forward against the COVID-19 pandemic, also marks the first use of mRNA vaccines
in humans. The use of mRNA vaccines has huge potential for future vaccine development in
increasing the efficiency of vaccine production, the potential targets for vaccination, and the
effectiveness of the vaccines produced. A significant advantage of mRNA vaccines is that they
can be produced completely in vitro9, and can be manufactured in a extremely short time relative
to other live attenuated vaccines. mRNA vaccines inherently have a copy and paste design in
which the mRNA in the lipid nanoparticle can easily be modified to address different variant
strains and novel mutations which may arise within a virus. Such variants can already be seen in
SARS-CoV-2. Knowledge of the spike protein structure in addition to identification and
characterization of different neutralizing antibodies that bind SARS-CoV-2 and different epitopes
on the SARS-CoV-2 spike protein is essential for further vaccine development, improvement,
and modification.
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